Ligand Pharmaceuticals/$LGND

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ticker

$LGND
Primary listing

Industry

Pharmaceuticals

Employees

68

ISIN

US53220K5048

LGND Metrics

BasicAdvanced
$2.4B
-
-$7.11
0.76
-

What the Analysts think about LGND

Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.

Bulls say / Bears say

Ligand Pharmaceuticals' partner, Travere Therapeutics, received full FDA approval for FILSPARI® (sparsentan), a non-immunosuppressive treatment for IgA nephropathy, entitling Ligand to a 9% royalty on worldwide net sales. (stocktitan.net)
The company's strategic merger of its subsidiary Pelthos Therapeutics with Channel Therapeutics, accompanied by a $50.1 million private placement, is expected to enhance its commercial portfolio and pipeline. (stockanalysis.com)
Analysts have a 'Strong Buy' consensus on LGND stock, with an average 12-month price target of $144.71, indicating a potential upside of approximately 27.72% from the current price. (stockanalysis.com)
Ligand Pharmaceuticals reported a fourth-quarter loss of $31.1 million, translating to a loss per share of $1.64, raising concerns about its profitability. (webull.com)
State Street reduced its stake in Ligand Pharmaceuticals by 26.76%, decreasing its ownership from 5.31% to 3.85%, which may signal waning institutional confidence. (nasdaq.com)
The company's forward P/E ratio stands at 18.94, which may be considered high relative to its earnings, potentially indicating overvaluation. (cnbc.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

LGND Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

LGND Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LGND

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs